Amitriptyline + ketamine

20448811000001100

New Medicines

AmiKet · Postherpetic neuralgia

Information

AmiKet
New formulation
Maxim Pharmaceuticals
Maxim Pharmaceuticals

Development and Regulatory status

None
None
None

Category

A tricyclic antidepressant and an NMDA antagonist
Incidence in UK primary care is about 3 per 1,000 person-years. In England and Wales there are thought to be 225,000 new cases per year [1].
Postherpetic neuralgia
Topical

AmiKet · Chemotherapy-induced peripheral neuropathy (CPN)

Information

AmiKet
Licence extension / variation
Maxim Pharmaceuticals
Maxim Pharmaceuticals

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

A tricyclic antidepressant and an NMDA antagonist
Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irreversible condition that afflicts between 30 and 40 percent of patients undergoing chemotherapy [4]
Chemotherapy-induced peripheral neuropathy (CPN)
Topical